These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 21592407)
1. Systematic review of influenza resistance to the neuraminidase inhibitors. Thorlund K; Awad T; Boivin G; Thabane L BMC Infect Dis; 2011 May; 11():134. PubMed ID: 21592407 [TBL] [Abstract][Full Text] [Related]
2. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870 [TBL] [Abstract][Full Text] [Related]
3. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174 [TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080 [TBL] [Abstract][Full Text] [Related]
5. Influenza virus resistance to neuraminidase inhibitors. Samson M; Pizzorno A; Abed Y; Boivin G Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922 [TBL] [Abstract][Full Text] [Related]
7. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. McKimm-Breschkin JL Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894 [TBL] [Abstract][Full Text] [Related]
9. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866 [TBL] [Abstract][Full Text] [Related]
10. In vitro neuraminidase inhibitory concentration (IC Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161 [TBL] [Abstract][Full Text] [Related]
11. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670 [TBL] [Abstract][Full Text] [Related]
12. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
13. Neuraminidase inhibitors for preventing and treating influenza in children. Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949 [TBL] [Abstract][Full Text] [Related]
14. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. Ikematsu H; Kawai N; Kashiwagi S J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919 [TBL] [Abstract][Full Text] [Related]
15. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD002744. PubMed ID: 22513907 [TBL] [Abstract][Full Text] [Related]
16. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Dixit R; Khandaker G; Ilgoutz S; Rashid H; Booy R Infect Disord Drug Targets; 2013 Feb; 13(1):34-45. PubMed ID: 23675925 [TBL] [Abstract][Full Text] [Related]
17. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness. Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493 [TBL] [Abstract][Full Text] [Related]
18. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200 [TBL] [Abstract][Full Text] [Related]
20. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]